Release date: 2007-01-17
U.S. develops bioanalysis system Erenna for predicting heart disease
The US singulex company has developed a bioanalytical system erenna capable of detecting cardiac troponin i (ctni) in the blood. Ctni is a biomedical marker of known myocardial damage.
Erenna has been shown to have diagnostic capabilities consistent with the newly redefined acute myocardial infarction (ami) diagnostic criteria and has received attention and recommendations from the European Heart Association and the American Heart Association.
The erenna assay uses a patented direct single-molecule assay and user-defined clinical assays to quantify therapeutically significant biomarkers at the sub-pick (pg) level. Studies have shown that erenna can significantly reduce the background of the sample, identify dyes from other molecules, and have good repeatability and good signal/noise ratio.
Dr. philippe goix, president and CEO of singulex, said: "Using high-sensitivity detection methods, heart troponin levels can be detected in healthy people, and acute myocardial infarction is detected earlier than traditional methods." Shanghai Medical Device Industry Association
Disposable PE Film,Disposable Waterproof PE Film,Disposable PE Cling Film,Sheet Disposable PE Film
XINLE HUABAO MEDICAL PRODUCTS CO.,LTD. , https://www.golbaltravel.com